VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress

Lead Product(s): VB-601

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

New data implicating the potential of VBL's proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA) is being presented today at the European League Against Rheumatism (EULAR) 2020 E-Congress.

VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20

Lead Product(s): Ofranergene obadenovec,Paclitaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

DSMC reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. Study to proceed without modification.

VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

Lead Product(s): VB-601

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

VBL Therapeutics's anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.

VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier

Lead Product(s): Ofranergene obadenovec,Paclitaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

Details:

Following the positive interim analysis in the OVAL study, NanoCarrier, intends to extend the ongoing global Phase 3 OVAL clinical trial in ovarian cancer to patients in Japan.

VBL Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in I...

Lead Product(s): Ofranergene obadenovec,Bevacizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

In the Phase 2 study, patients with rGBM who were primed with VB-111 monotherapy that was continued after progression with the addition of bevacizumab (Avastin®) showed significant survival.

Find

Find Clinical Drug Pipeline Developments & Deals by VBL Therapeutics

Pipeline Prospector Find Drug Development Pipeline & Deal Updates

Companies By Therapeutic Area

Development Status

VBL Therapeutics

VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress

VBL Therapeutics

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20

VBL Therapeutics

VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation

VBL Therapeutics

Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier

VBL Therapeutics

VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in I...